SAN DIEGO--On August 28, following the successful close of its second round of funding, Structural Bioinformatics elected three new directors to its board. The appointees include Edgar Engleman, John Kenward, and Frank Kung.
Engleman is professor of medicine and pathology at the Stanford School of Medicine and is the cofounder of several companies. Kenward is a former executive of several pharmaceutical and biotechnology companies, including Ixsys, where he served as CEO, RepliGen, and Schering Plough. Kung has worked in the biotechnology industry for almost 20 years and has received numerous awards.
Structural Bioinformatics is the developer of a supercomputational operating system that makes possible the immediate use of gene sequence data in a broad range of structure-based drug discovery and design processes. The company is building corporate partnerships with pharmaceutical companies, gene discovery companies, and combinatorial chemistry companies.